Kamada (NASDAQ:KMDA) Issues Earnings Results

Kamada (NASDAQ:KMDA) announced its quarterly earnings data on Monday. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01, FiscalAI reports. Kamada had a return on equity of 8.37% and a net margin of 11.60%. The business had revenue of $52.03 million during the quarter, compared to analyst estimates of $52.51 million.

Kamada Stock Performance

KMDA opened at $7.23 on Monday. The stock has a market capitalization of $415.80 million, a P/E ratio of 19.03, a P/E/G ratio of 0.61 and a beta of 0.90. The company’s 50-day simple moving average is $8.08 and its two-hundred day simple moving average is $8.00. Kamada has a 52-week low of $6.55 and a 52-week high of $9.35.

Kamada Cuts Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were given a $0.17 dividend. This is a negative change from Kamada’s previous annual dividend of $0.25. The ex-dividend date of this dividend was Thursday, August 27th. This represents a yield of 206.0%. Kamada’s payout ratio is presently 34.21%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on KMDA shares. Weiss Ratings raised shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. William Blair set a $15.00 target price on shares of Kamada in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Benchmark restated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Finally, UBS Group restated a “buy” rating and issued a $15.00 price objective on shares of Kamada in a report on Friday, September 18th. Four analysts have rated the stock with a Buy rating. According to MarketBeat, Kamada presently has an average rating of “Buy” and an average target price of $13.50.

About Kamada

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.